THE Purchase Manage R Health City Cayman Island Limited Pharmaceutical Import Profile — United Kingdom (DGFT 2022–2026)

Name: THE Purchase Manage R Health City Cayman Island Limited Pharmaceutical Import Records from India — 2 Products, $30.9K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

THE Purchase Manage R Health City Cayman Island Limited — Pharmaceutical Importer Profile (2026) | 2 Products, $30.9K Trade | TransData Nexus

THE Purchase Manage R Health City Cayman Island Limited

Pharmaceutical Importer · United Kingdom · Advanced Oncology Focus · $30.9K Total Trade · DGFT Verified

THE Purchase Manage R Health City Cayman Island Limited is a pharmaceutical importer based in United Kingdom with a total trade value of $30.9K across 2 products in 1 therapeutic categories. Based on 8 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. THE Purchase Manage R Health City Cayman Island Limited sources from 1 verified Indian supplier, with Miles International accounting for 100.0% of imports.

THE Purchase Manage R Health City Cayman Island Limited — Import Portfolio & Supplier Network

THE Purchase Manage R Health City Cayman Island Limited import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to THE Purchase Manage R Health City Cayman Island Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Miles International	$175.9K	80	100.0%

THE Purchase Manage R Health City Cayman Island Limited sources from 1 verified Indian supplier across 64 distinct formulations. The sourcing is highly concentrated — Miles International accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
[tax document no. be-319; gstin. 33aavfb9641f1z6] mepilex border sacrum 16 x	$32.8K	1
[tax document no. 29 & 31; gstin. 33aavfb9641f1z6] mepilex border sacrum 22 x 25	$17.9K	2
[tax document no. ghwl/2324/044; gstin. 27aaxfg4500g1za] darolutamide 300MG nubeqapack: 7 x 16	$17.1K	1
[tax document no. thc000020; gstin. 27aanft3310m1zw] enzalutamide capsule xtandi 40MG [Pack: 112	$14.6K	2
[tax document no. w0193; gstin. 27aabcf6135b1z2] daratumumab injection darzalex 400MG	$12.2K	4
[tax document no. thc000019; gstin. 27aanft3310m1zw] cetuximab injection erbitux 500MG	$11.2K	2
[tax document no. 75; gstin. 33aavfb9641f1z6]mepilex border sacrum	$8.6K	1
[tax document no. 31; gstin. 33aavfb9641f1z6]mepilex border sacrum 22 x 25	$7.5K	1
[tax document no. w0193; gstin. 27aabcf6135b1z2] daratumumab injection darzalex 100MG	$7.5K	2
[tax document no. wh0325; gstin. 27aaccn8725e1zf] denosumab injection xgeva 120MG	$4.2K	2
[tax document no. ylc009065; gstin. 27cihpm0204p1z4] lenvatinib capsules lenvima 4MG Pack: 10 CAPS	$3.5K	1
[tax document no. w/18760 & rbc004002 ; gstin. 27aasfr4559h1zj & 27aaser8882r1zo] infiliximab 100MG injection	$3.1K	1
[tax document no. 29; gstin. 33aavfb9641f1z6]mepilex border sacrum 22 x 25	$2.8K	1
[tax document no. thc000021; gstin. 27aanft3310m1zw] carfilzamib injection kyprolis60mg	$2.6K	2
[tax document no. thc000022; gstin. 27aanft3310m1zw] carfilzamib injection 60MG kyprolis	$2.5K	1

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Daratumumab	Advanced Oncology	$19.7K	6	1.5%	11
2	Cetuximab	Advanced Oncology	$11.2K	2	1.3%	4

THE Purchase Manage R Health City Cayman Island Limited imports 2 pharmaceutical products across 1 categories into United Kingdom totaling $30.9K.

THE Purchase Manage R Health City Cayman Island Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

THE Purchase Manage R Health City Cayman Island Limited is a pharmaceutical importer based in the United Kingdom, specializing in the procurement of finished pharmaceutical formulations. The company operates as a buyer, sourcing medications from international suppliers to meet the needs of the UK market. While the exact nature of its operations—whether as a wholesaler, distributor, or other role—is not explicitly detailed in the available data, its activities suggest a focus on importing and distributing pharmaceutical products within the United Kingdom.

The company's headquarters are located at 1283 Sea View Road, PO Box 10590, Grand Cayman, KY1-1005, Cayman Islands. This location indicates a strategic positioning to facilitate international trade and logistics. The parent company is not specified in the available information, and there is no indication of its role in the United Kingdom's pharmaceutical distribution network.

2Distribution Network

Specific details regarding THE Purchase Manage R Health City Cayman Island Limited's warehouse locations, logistics capabilities, and geographic coverage within the United Kingdom are not provided in the available data. However, the company's import activities suggest a distribution network that spans the UK, ensuring the availability of imported pharmaceutical products to meet domestic demand.

3Industry Role

Based on the available information, THE Purchase Manage R Health City Cayman Island Limited functions primarily as a pharmaceutical importer. Its role in the UK's pharmaceutical supply chain involves sourcing finished pharmaceutical formulations from international suppliers and distributing them within the UK market. The company's focus on importing specific products indicates a targeted approach to fulfilling particular market needs.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — THE Purchase Manage R Health City Cayman Island Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

THE Purchase Manage R Health City Cayman Island Limited's sourcing strategy exhibits a high degree of concentration, with all its imports originating from a single supplier, Miles International. This single-source dependency could pose risks related to supply chain disruptions, pricing fluctuations, and potential challenges in negotiating favorable terms. The shipment data indicates a consistent relationship, with 80 shipments valued at $176K, suggesting a stable and ongoing partnership. However, the lack of diversification in suppliers may limit the company's ability to mitigate risks associated with supplier-specific issues.

2Supply Chain Resilience

The resilience of THE Purchase Manage R Health City Cayman Island Limited's supply chain is closely tied to its exclusive reliance on Miles International for sourcing pharmaceutical products. This singular supplier relationship may expose the company to vulnerabilities in the event of supply disruptions, regulatory changes, or other challenges faced by Miles International. The absence of backup suppliers and limited formulation diversity further accentuate these risks. Additionally, the company's shipping route exposure and the regulatory compliance status of Miles International are not detailed, which are critical factors in assessing overall supply chain resilience.

Importing Pharmaceuticals into United Kingdom — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United Kingdom

1Regulatory Authority & Framework

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) serves as the primary regulatory authority overseeing pharmaceutical imports. The MHRA is responsible for ensuring that medicines and medical devices meet appropriate standards of safety, quality, and efficacy. Key legislation governing pharmaceutical imports includes the Human Medicines Regulations 2012, which transposes EU directives into UK law, and the Medicines Act 1968. The marketing authorization pathway for Indian generics involves obtaining a UK marketing authorization, which can be achieved through the centralized procedure via the European Medicines Agency (EMA) or by obtaining a UK-specific marketing authorization.

2Import Licensing & GMP

Import licensing requirements in the UK stipulate that pharmaceutical products must be accompanied by a valid marketing authorization. Good Manufacturing Practice (GMP) certificates from recognized authorities, such as the European Union (EU) GMP, World Health Organization (WHO) GMP, or Pharmaceutical Inspection Co-operation Scheme (PIC/S), are essential for ensuring product quality and safety. Wholesale distribution authorization is also required, which involves compliance with the MHRA's Good Distribution Practice (GDP) guidelines to maintain the integrity of the supply chain.

THE Purchase Manage R Health City Cayman Island Limited — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

THE Purchase Manage R Health City Cayman Island Limited's product category focus on advanced oncology reflects a strategic decision to address the significant demand for cancer treatments in the UK. The importation of Daratumumab and Cetuximab, both critical in oncology, indicates a targeted approach to fulfilling specific therapeutic needs. Market demand for these products is driven by the prevalence of certain cancers and the need for effective treatment options, positioning the company to meet a vital segment of the healthcare market.

2Sourcing Profile

The company's sourcing strategy is centered on importing generic drugs, particularly in the oncology therapeutic area. This focus allows for cost-effective procurement while ensuring access to essential medications. India's role as a major supplier of generic pharmaceuticals aligns with THE Purchase Manage R Health City Cayman Island Limited's procurement approach, leveraging India's manufacturing capabilities and competitive pricing to meet the UK's healthcare needs.

3Market Positioning

Based on its product mix, THE Purchase Manage R Health City Cayman Island Limited serves the hospital segment of the UK market. The importation of specialized oncology medications suggests a focus on supplying hospitals and healthcare institutions that require these treatments. The company's role in the supply chain is likely that of a wholesaler or distributor, ensuring that these critical medications are available to healthcare providers for patient care.

Seller's Guide — How to Become a Supplier to THE Purchase Manage R Health City Cayman Island Limited

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with THE Purchase Manage R Health City Cayman Island Limited, especially if they can offer competitive pricing, reliable supply chains, and compliance with UK regulatory standards. Gaps in the company's current sourcing include the potential for diversification of suppliers to mitigate risks associated with single-source dependency. Additionally, expanding the range of imported formulations could address broader market needs and enhance the company's product portfolio.

2Requirements & Qualifications

Indian exporters seeking to supply THE Purchase Manage R Health City Cayman Island Limited and the UK market must ensure that their products meet the MHRA's regulatory requirements, including obtaining a valid marketing authorization and adhering to GMP standards recognized by the MHRA. Products must also comply with labeling and serialization mandates. Establishing a wholesale distribution authorization and adhering to GDP guidelines are essential for maintaining the integrity of the supply chain.

3How to Approach

Frequently Asked Questions — THE Purchase Manage R Health City Cayman Island Limited

What products does THE Purchase Manage R Health City Cayman Island Limited import from India?

THE Purchase Manage R Health City Cayman Island Limited imports 2 pharmaceutical products across 1 categories. Top imports: Daratumumab ($19.7K), Cetuximab ($11.2K).

Who supplies pharmaceuticals to THE Purchase Manage R Health City Cayman Island Limited from India?

THE Purchase Manage R Health City Cayman Island Limited sources from 1 verified Indian suppliers. The primary supplier is Miles International (100.0% of imports, $175.9K).

What is THE Purchase Manage R Health City Cayman Island Limited's total pharmaceutical import value?

THE Purchase Manage R Health City Cayman Island Limited's total pharmaceutical import value from India is $30.9K, based on 8 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does THE Purchase Manage R Health City Cayman Island Limited focus on?

THE Purchase Manage R Health City Cayman Island Limited imports across 1 categories. The largest: Advanced Oncology (100.0%).

Get Full THE Purchase Manage R Health City Cayman Island Limited Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.